InterVenn Biosciences Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$201M
- Investors
-
13
InterVenn Biosciences General Information
Description
Developer of a biomarker and target discovery platform designed to help in the detection and triaging of ovarian and other cancers. The company's platform focuses on the identification, quantification and classification of glycoproteomic and PTM signals found in human blood and tissue for target discovery and validation, enabling healthcare providers to diagnose cancer at an early stage and improve patient care.
Contact Information
Website
www.intervenn.comCorporate Office
- 2 Tower Place
- 5th Floor
- South San Francisco, CA 94080
- United States
Corporate Office
- 2 Tower Place
- 5th Floor
- South San Francisco, CA 94080
- United States
InterVenn Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series C) | 02-Aug-2021 | $201M | Completed | Generating Revenue | ||
| 3. Early Stage VC (Series B) | 14-Sep-2020 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 12-Dec-2018 | $9.4M | $9.5M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | 01-Jan-2018 | $50K | $50K | Completed | Startup |
InterVenn Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 9,398,269 | $0.010000 | 8% | $1 | $1 | 1x | $1 | 13.8% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
InterVenn Biosciences Comparisons
Industry
Financing
Details
InterVenn Biosciences Competitors (30)
One of InterVenn Biosciences’s 30 competitors is Paige, a Formerly VC-backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Paige | Formerly VC-backed | New York, NY | ||||
| InsightRx | Venture Capital-Backed | San Francisco, CA | ||||
| CureMetrix | Venture Capital-Backed | San Diego, CA | ||||
| Infervision | Venture Capital-Backed | Beijing, China | ||||
| Freenome | Formerly VC-backed | Brisbane, CA |
InterVenn Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
InterVenn Biosciences Patents
InterVenn Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025024433-A1 | Fucosylated pd-1 variants for determining an immuno-oncology response | Inactive | 25-Jul-2023 | ||
| WO-2025006267-A1 | Peptide biomarkers for diagnosing primary sclerosing cholangitis or primary biliary cholangitis | Inactive | 26-Jun-2023 | ||
| WO-2024242714-A1 | Methods and systems for analyzing site-specific monomer composition | Inactive | 22-May-2023 | ||
| WO-2024232928-A1 | Biomarkers for diagnosing non-small cell lung cancer (nsclc) | Inactive | 09-May-2023 | ||
| US-20240379228-A1 | Diagnosis of colorectal cancer using targeted quantification of peptides | Pending | 08-May-2023 | G01N33/6848 |
InterVenn Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
InterVenn Biosciences Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AG Hill Partners | Family Office | Minority | ||
| Heritage Provider Network | Corporation | Minority | ||
| Highside Capital Management | Hedge Fund | Minority | ||
| Irving Investors | Growth/Expansion | Minority | ||
| SoftBank Investment Advisers | Growth/Expansion | Minority |
InterVenn Biosciences FAQs
-
When was InterVenn Biosciences founded?
InterVenn Biosciences was founded in 2017.
-
Where is InterVenn Biosciences headquartered?
InterVenn Biosciences is headquartered in South San Francisco, CA.
-
What is the size of InterVenn Biosciences?
InterVenn Biosciences has 15 total employees.
-
What industry is InterVenn Biosciences in?
InterVenn Biosciences’s primary industry is Decision/Risk Analysis.
-
Is InterVenn Biosciences a private or public company?
InterVenn Biosciences is a Private company.
-
What is the current valuation of InterVenn Biosciences?
The current valuation of InterVenn Biosciences is .
-
What is InterVenn Biosciences’s current revenue?
The current revenue for InterVenn Biosciences is .
-
How much funding has InterVenn Biosciences raised over time?
InterVenn Biosciences has raised $244M.
-
Who are InterVenn Biosciences’s investors?
AG Hill Partners, Heritage Provider Network, Highside Capital Management, Irving Investors, and SoftBank Investment Advisers are 5 of 13 investors who have invested in InterVenn Biosciences.
-
Who are InterVenn Biosciences’s competitors?
Paige, InsightRx, CureMetrix, Infervision, and Freenome are some of the 30 competitors of InterVenn Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
